Trial Outcomes & Findings for Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever) (NCT NCT02663674)

Results Overview

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

72 participants

Primary outcome timeframe

Visit 2 (Day 20-23)

Results posted on

2019-07-05

Participant Flow

Recruitment occurred between Feb 2016 and May 2018 at community locations in Coccidioides-endemic areas. Participants were adults presenting with community acquired pneumonia (CAP) whose health care provider had made the decision to treat with an antibacterial.

Participant milestones

Participant milestones
Measure	Fluconazole Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Overall Study STARTED	33	39
Overall Study COMPLETED	26	29
Overall Study NOT COMPLETED	7	10

Reasons for withdrawal

Reasons for withdrawal
Measure	Fluconazole Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Overall Study Lost to Follow-up	5	4
Overall Study Withdrawal by Subject	1	4
Overall Study Physician Decision	1	1
Overall Study Other Event (Health Related)	0	1

Baseline Characteristics

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Fluconazole n=33 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=39 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.	Total n=72 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	25 Participants n=5 Participants	33 Participants n=7 Participants	58 Participants n=5 Participants
Age, Categorical >=65 years	8 Participants n=5 Participants	6 Participants n=7 Participants	14 Participants n=5 Participants
Age, Continuous	50.1 years STANDARD_DEVIATION 16.1 • n=5 Participants	49.5 years STANDARD_DEVIATION 12.6 • n=7 Participants	49.8 years STANDARD_DEVIATION 14.2 • n=5 Participants
Sex: Female, Male Female	18 Participants n=5 Participants	18 Participants n=7 Participants	36 Participants n=5 Participants
Sex: Female, Male Male	15 Participants n=5 Participants	21 Participants n=7 Participants	36 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	16 Participants n=5 Participants	19 Participants n=7 Participants	35 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	17 Participants n=5 Participants	20 Participants n=7 Participants	37 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	4 Participants n=5 Participants	4 Participants n=7 Participants	8 Participants n=5 Participants
Race (NIH/OMB) White	26 Participants n=5 Participants	31 Participants n=7 Participants	57 Participants n=5 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants
Region of Enrollment United States	33 participants n=5 Participants	39 participants n=7 Participants	72 participants n=5 Participants
Positive for coccidioidomycosis pneumonia	4 Participants n=5 Participants	4 Participants n=7 Participants	8 Participants n=5 Participants

PRIMARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected capsules.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Proportion of Participants Who Achieve a Clinical Response, Defined as at Least a 50% Reduction in Composite FLEET CAP Score From Baseline, in the Cocci-positive Per-protocol Population	3 Participants	2 Participants

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=3 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Proportion of Participants Who Achieve a Clinical Response, Defined as at Least a 50% Reduction in Composite FLEET CAP Score From Baseline, in the Cocci Positive Modified Intent-to-Treat Population	3 Participants	2 Participants

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Proportion of Participants Who Achieve a Clinical Response, Defined as at Least a 50% Reduction in Composite FLEET CAP Score From Baseline, in the All Randomized mITT Population	20 Participants	22 Participants

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The population includes all participants who took at least one dose of study medication.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Proportion of Participants Who Achieve a Clinical Response, Defined as at Least a 50% Reduction in Composite FLEET CAP Score From Baseline, in All Randomized Participants Who Took at Least One Dose of Study Medication	20 Participants	22 Participants

SECONDARY outcome

Timeframe: Visit 2 - Visit 4 (Day 20-46)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome. Note that a participant who responds earlier before Day 43 does not need to achieve a clinical response at Day 43, as well.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Proportion of Participants Who Achieve a Clinical Response, Defined as at Least a 50% Reduction in Composite FLEET CAP Score From Baseline, in the Cocci Positive Modified Intent-to-Treat Population	4 Participants	2 Participants

SECONDARY outcome

Timeframe: Visit 2 - Visit 4 (Day 20-46)

Population: The population includes all participants who took at least one dose of study medication.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome. Note that a participant who responds earlier before Day 43 does not need to achieve a clinical response at Day 43, as well.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Proportion of Participants Who Achieve a Clinical Response, Defined as at Least a 50% Reduction in Composite FLEET CAP Score From Baseline, in All Randomized Participants Who Took at Least One Dose of Study Medication	25 Participants	28 Participants

SECONDARY outcome

Timeframe: Visit 2 - Visit 4 (Day 20-46)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome. Note that a participant who responds earlier before Day 43 does not need to achieve a clinical response at Day 43, as well.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Proportion of Participants Who Achieve a Clinical Response, Defined as at Least a 50% Reduction in Composite FLEET CAP Score From Baseline, in the All Randomized mITT Population	25 Participants	28 Participants

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Total FLEET CAP Score	3.04 score on a scale Interval 1.0 to 5.0	3.49 score on a scale Interval 1.0 to 6.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Cough	0.85 score on a scale Interval 0.0 to 2.0	0.86 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fatigue	0.74 score on a scale Interval 0.0 to 1.0	0.74 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Chest Pain	0.11 score on a scale Interval 0.0 to 0.0	0.31 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Dyspnea	0.48 score on a scale Interval 0.0 to 1.0	0.60 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Sputum Production	0.41 score on a scale Interval 0.0 to 1.0	0.40 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Night Sweats	0.26 score on a scale Interval 0.0 to 0.0	0.37 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Hypoxia	0.19 score on a scale Interval 0.0 to 0.0	0.20 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Total FLEET CAP Score	2.00 score on a scale Interval 1.0 to 5.0	2.00 score on a scale Interval 1.0 to 6.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Cough	1 score on a scale Interval 0.0 to 2.0	1 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fatigue	1 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Dyspnea	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Sputum Production	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Total FLEET CAP Score	2.58 score on a scale Interval 0.0 to 4.0	1.97 score on a scale Interval 0.0 to 2.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Cough	0.73 score on a scale Interval 0.0 to 1.0	0.48 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fatigue	0.62 score on a scale Interval 0.0 to 1.0	0.42 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Chest Pain	0.19 score on a scale Interval 0.0 to 0.0	0.13 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Dyspnea	0.46 score on a scale Interval 0.0 to 1.0	0.42 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Sputum Production	0.31 score on a scale Interval 0.0 to 0.0	0.16 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Night Sweats	0.15 score on a scale Interval 0.0 to 0.0	0.19 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Hypoxia	0.12 score on a scale Interval 0.0 to 0.0	0.16 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Total FLEET CAP Score	2 score on a scale Interval 0.0 to 4.0	1 score on a scale Interval 0.0 to 2.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Cough	1 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fatigue	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Dyspnea	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Total FLEET CAP Score	1.36 score on a scale Interval 0.0 to 2.0	1.5 score on a scale Interval 0.0 to 2.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Cough	0.44 score on a scale Interval 0.0 to 1.0	0.23 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fatigue	0.36 score on a scale Interval 0.0 to 1.0	0.37 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Chest Pain	0.08 score on a scale Interval 0.0 to 0.0	0.17 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Dyspnea	0.12 score on a scale Interval 0.0 to 0.0	0.30 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Sputum Production	0.24 score on a scale Interval 0.0 to 0.0	0.13 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Night Sweats	0.04 score on a scale Interval 0.0 to 0.0	0.10 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Hypoxia	0.08 score on a scale Interval 0.0 to 0.0	0.20 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Total FLEET CAP Score	1 score on a scale Interval 0.0 to 2.0	1 score on a scale Interval 0.0 to 2.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Cough	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fatigue	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Dyspnea	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the ITT Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=3 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	2.25 score on a scale Interval 1.0 to 3.5	3.67 score on a scale Interval 0.0 to 10.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Cough	0.5 score on a scale Interval 0.0 to 1.0	1 score on a scale Interval 0.0 to 2.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fatigue	1.00 score on a scale Interval 0.5 to 1.5	1.00 score on a scale Interval 0.0 to 3.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Dyspnea	0.5 score on a scale Interval 0.0 to 1.0	0.67 score on a scale Interval 0.0 to 2.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0.33 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Night Sweats	0.25 score on a scale Interval 0.0 to 0.5	0.67 score on a scale Interval 0.0 to 2.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=3 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	1 score on a scale Interval 1.0 to 3.5	1 score on a scale Interval 0.0 to 10.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Cough	0 score on a scale Interval 0.0 to 1.0	1 score on a scale Interval 0.0 to 2.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fatigue	1 score on a scale Interval 0.5 to 1.5	0 score on a scale Interval 0.0 to 3.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Dyspnea	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 2.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Night Sweats	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 2.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	1.00 score on a scale Interval 0.0 to 2.0	0.5 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Cough	0.5 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fatigue	0.25 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Dyspnea	0.25 score on a scale Interval 0.0 to 0.5	0.5 score on a scale Interval 0.0 to 1.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	0.5 score on a scale Interval 0.0 to 2.0	0.5 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Cough	0.5 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fatigue	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Dyspnea	0 score on a scale Interval 0.0 to 0.5	0.5 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	0.75 score on a scale Interval 0.0 to 1.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Cough	0.25 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fatigue	0.25 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Dyspnea	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Hypoxia	0.25 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	0 score on a scale Interval 0.0 to 1.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Cough	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fatigue	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Dyspnea	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Modified Intent-to-Treat (mITT) Population Hypoxia	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	3.04 score on a scale Interval 1.0 to 5.0	3.49 score on a scale Interval 1.0 to 6.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Cough	0.85 score on a scale Interval 0.0 to 2.0	0.86 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fatigue	0.74 score on a scale Interval 0.0 to 1.0	0.74 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Chest Pain	0.11 score on a scale Interval 0.0 to 0.0	0.31 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Dyspnea	0.48 score on a scale Interval 0.0 to 1.0	0.6 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Sputum Production	0.41 score on a scale Interval 0.0 to 1.0	0.40 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Night Sweats	0.26 score on a scale Interval 0.0 to 0.0	0.37 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Hypoxia	0.19 score on a scale Interval 0.0 to 0.0	0.20 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	2 score on a scale Interval 1.0 to 5.0	2 score on a scale Interval 1.0 to 6.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Cough	1 score on a scale Interval 0.0 to 2.0	1 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fatigue	1 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Dyspnea	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Sputum Production	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	2.58 score on a scale Interval 0.0 to 4.0	1.97 score on a scale Interval 0.0 to 2.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Cough	0.73 score on a scale Interval 0.0 to 1.0	0.48 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fatigue	0.62 score on a scale Interval 0.0 to 1.0	0.42 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Chest Pain	0.19 score on a scale Interval 0.0 to 0.0	0.13 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Dyspnea	0.46 score on a scale Interval 0.0 to 1.0	0.42 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Sputum Production	0.31 score on a scale Interval 0.0 to 0.0	0.16 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Night Sweats	0.15 score on a scale Interval 0.0 to 0.0	0.19 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Hypoxia	0.12 score on a scale Interval 0.0 to 0.0	0.16 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	2 score on a scale Interval 0.0 to 4.0	1 score on a scale Interval 0.0 to 2.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Cough	1 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fatigue	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Dyspnea	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	1.36 score on a scale Interval 0.0 to 2.0	1.5 score on a scale Interval 0.0 to 2.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Cough	0.44 score on a scale Interval 0.0 to 1.0	0.23 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fatigue	0.36 score on a scale Interval 0.0 to 1.0	0.37 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Chest Pain	0.08 score on a scale Interval 0.0 to 0.0	0.17 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Dyspnea	0.12 score on a scale Interval 0.0 to 0.0	0.30 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Sputum Production	0.24 score on a scale Interval 0.0 to 0.0	0.13 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Night Sweats	0.04 score on a scale Interval 0.0 to 0.0	0.10 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Hypoxia	0.08 score on a scale Interval 0.0 to 0.0	0.20 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Total FLEET CAP Score	1 score on a scale Interval 0.0 to 2.0	1 score on a scale Interval 0.0 to 2.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Cough	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fatigue	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Dyspnea	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Modified Intent-to-Treat (mITT) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Total FLEET CAP Score	2.25 score on a scale Interval 1.0 to 3.5	0.5 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Cough	0.5 score on a scale Interval 0.0 to 1.0	0.5 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fatigue	1.00 score on a scale Interval 0.5 to 1.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Dyspnea	0.5 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Night Sweats	0.25 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Total FLEET CAP Score	1 score on a scale Interval 1.0 to 3.5	0.5 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Cough	0 score on a scale Interval 0.0 to 1.0	0.5 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Dyspnea	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fatigue	1 score on a scale Interval 0.5 to 1.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Night Sweats	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Total FLEET CAP Score	1.00 score on a scale Interval 0.0 to 2.0	0.5 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Cough	0.5 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fatigue	0.25 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Dyspnea	0.25 score on a scale Interval 0.0 to 0.5	0.5 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Dyspnea	0 score on a scale Interval 0.0 to 0.5	0.5 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Total FLEET CAP Score	0.5 score on a scale Interval 0.0 to 2.0	0.5 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Cough	0.5 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fatigue	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Total FLEET CAP Score	0.75 score on a scale Interval 0.0 to 1.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Cough	0.25 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fatigue	0.25 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Dyspnea	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Hypoxia	0.25 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Cough	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Dyspnea	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Total FLEET CAP Score	0 score on a scale Interval 0.0 to 1.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fatigue	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the Cocci Positive Per-Protocol (PP) Population Hypoxia	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=29 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Total FLEET CAP Score	2.64 score on a scale Interval 1.0 to 4.0	3.72 score on a scale Interval 1.0 to 6.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Cough	0.80 score on a scale Interval 0.0 to 1.0	0.97 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fatigue	0.72 score on a scale Interval 0.0 to 1.0	0.76 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Chest Pain	0.08 score on a scale Interval 0.0 to 0.0	0.34 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Dyspnea	0.40 score on a scale Interval 0.0 to 1.0	0.66 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Sputum Production	0.32 score on a scale Interval 0.0 to 1.0	0.45 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Night Sweats	0.16 score on a scale Interval 0.0 to 0.0	0.38 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Hypoxia	0.16 score on a scale Interval 0.0 to 0.0	0.17 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=29 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Total FLEET CAP Score	2 score on a scale Interval 1.0 to 4.0	3 score on a scale Interval 1.0 to 6.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Cough	1 score on a scale Interval 0.0 to 1.0	1 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fatigue	1 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Dyspnea	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Sputum Production	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=25 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fatigue	0.63 score on a scale Interval 0.0 to 1.0	0.44 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Dyspnea	0.42 score on a scale Interval 0.0 to 1.0	0.44 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Sputum Production	0.33 score on a scale Interval 0.0 to 0.5	0.16 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Total FLEET CAP Score	2.42 score on a scale Interval 0.0 to 3.5	1.96 score on a scale Interval 0.0 to 2.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Cough	0.71 score on a scale Interval 0.0 to 1.0	0.48 score on a scale Interval 0.0 to 1.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Chest Pain	0.17 score on a scale Interval 0.0 to 0.0	0.12 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Night Sweats	0.08 score on a scale Interval 0.0 to 0.0	0.20 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Hypoxia	0.08 score on a scale Interval 0.0 to 0.0	0.12 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=25 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fatigue	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Total FLEET CAP Score	2 score on a scale Interval 0.0 to 3.5	1 score on a scale Interval 0.0 to 2.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Cough	1 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Dyspnea	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 1.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Sputum Production	0 score on a scale Interval 0.0 to 0.5	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=23 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=24 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Cough	0.35 score on a scale Interval 0.0 to 1.0	0.21 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Chest Pain	0.04 score on a scale Interval 0.0 to 0.0	0.13 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Sputum Production	0.13 score on a scale Interval 0.0 to 0.0	0.08 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Night Sweats	0.04 score on a scale Interval 0.0 to 0.0	0.08 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Total FLEET CAP Score	1.09 score on a scale Interval 0.0 to 2.0	1.25 score on a scale Interval 0.0 to 2.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fatigue	0.35 score on a scale Interval 0.0 to 1.0	0.38 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Dyspnea	0.09 score on a scale Interval 0.0 to 0.0	0.21 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Mean and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Hypoxia	0.09 score on a scale Interval 0.0 to 0.0	0.17 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=23 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=24 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fatigue	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Chest Pain	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Total FLEET CAP Score	0 score on a scale Interval 0.0 to 2.0	0.5 score on a scale Interval 0.0 to 2.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Cough	0 score on a scale Interval 0.0 to 1.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Dyspnea	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Sputum Production	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Night Sweats	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Fever	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0
The Median and Quartiles of the FLEET CAP Score and Each Component in the All Randomized Per-Protocol (PP) Population Hypoxia	0 score on a scale Interval 0.0 to 0.0	0 score on a scale Interval 0.0 to 0.0

SECONDARY outcome

Timeframe: Visit 1 (Day 1) through Visit 4 (Day 42-46)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

Number of the days of school or work missed due to illness by participant self-report

Outcome measures

Outcome measures
Measure	Fluconazole n=19 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=23 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of the Days of School or Work Missed Due to Illness in the ITT Population	0 days Standard Deviation 0	1.5 days Standard Deviation 5.2

SECONDARY outcome

Timeframe: Visit 1 (Day 1) through Visit 4 (Day 42-46)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

Number of the days of school or work missed due to illness by participant self-report

Outcome measures

Outcome measures
Measure	Fluconazole n=2 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of the Days of School or Work Missed Due to Illness in the Cocci Positive mITT Population	0 days Standard Deviation 0	—

SECONDARY outcome

Timeframe: Visit 1 (Day 1) through Visit 4 (Day 42-46)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

Number of the days of school or work missed due to illness by participant self-report

Outcome measures

Outcome measures
Measure	Fluconazole n=18 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=17 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of the Days of School or Work Missed Due to Illness in the All Randomized PP Population	0 days Standard Deviation 0	0.6 days Standard Deviation 1.8

SECONDARY outcome

Timeframe: Visit 1 (Day 1) through Visit 4 (Day 42-46)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

Number of the days of school or work missed due to illness by participant self-report

Outcome measures

Outcome measures
Measure	Fluconazole n=2 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of the Days of School or Work Missed Due to Illness in the Cocci Positive PP Population	0 days Standard Deviation 0	—

SECONDARY outcome

Timeframe: Visit 1 (Day 1) through Visit 4 (Day 42-46)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

Number of the days of school or work missed due to illness by participant self-report

Outcome measures

Outcome measures
Measure	Fluconazole n=19 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=23 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of the Days of School or Work Missed Due to Illness in the All Randomized mITT Population	0 days Standard Deviation 0	1.5 days Standard Deviation 5.2

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Always	15 Participants	13 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Never	0 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Usually	5 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Rarely	5 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Sometimes	7 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Usually	4 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Never	1 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Rarely	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Sometimes	7 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Usually	3 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Rarely	3 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Sometimes	4 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Always	15 Participants	15 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Always	11 Participants	13 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Never	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Rarely	3 Participants	2 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Sometimes	5 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Usually	4 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Always	14 Participants	12 Participants

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Sometimes	6 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Usually	4 Participants	13 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Always	13 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Usually	5 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Rarely	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Rarely	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Sometimes	6 Participants	11 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Usually	4 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Always	14 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Rarely	4 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Sometimes	5 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Usually	4 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Always	13 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Rarely	2 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Sometimes	6 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Always	13 Participants	11 Participants

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Always	14 Participants	12 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Rarely	2 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Sometimes	5 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Usually	4 Participants	11 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Usually	4 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Rarely	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Sometimes	6 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Usually	4 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Usually	2 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Always	16 Participants	15 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Never	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Rarely	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Sometimes	5 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Always	14 Participants	11 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Rarely	2 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Sometimes	5 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Always	14 Participants	16 Participants

SECONDARY outcome

Timeframe: Visit 6 (Day 83-97)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Never	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 7 (Day 173-187)

Population: The Intent-to-Treat (ITT) population includes all randomized participants.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Usually	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the ITT Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Usually	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Usually	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Always	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Usually	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Always	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Usually	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Always	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Usually	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Always	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Usually	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Always	2 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Always	3 Participants	2 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Always	3 Participants	2 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Always	3 Participants	2 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Usually	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Visit 6 (Day 83-97)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Never	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 7 (Day 173-187)

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Usually	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive Per Protocol Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=3 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Never	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Never	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Usually	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Usually	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Always	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Never	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Always	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Usually	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Always	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Usually	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Always	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Usually	1 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Always	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Usually	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Always	3 Participants	2 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Always	3 Participants	2 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Usually	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Always	3 Participants	2 Participants

SECONDARY outcome

Timeframe: Visit 6 (Day 83-97)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Never	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 7 (Day 173-187)

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Usually	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the Cocci Positive mITT Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=29 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Rarely	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	7 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Usually	3 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Always	14 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Rarely	2 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Sometimes	4 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Usually	5 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Always	14 Participants	11 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Never	0 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	5 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	5 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Usually	4 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Always	11 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	2 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Rarely	3 Participants	2 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	5 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Usually	4 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Always	13 Participants	8 Participants

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=25 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Usually	4 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	4 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Always	12 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Rarely	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	5 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Usually	4 Participants	13 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Always	12 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Rarely	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Sometimes	5 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Always	13 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	4 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Usually	4 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Always	12 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Rarely	2 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	5 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Usually	5 Participants	9 Participants

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=23 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=24 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Rarely	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	5 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Usually	4 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Always	13 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Rarely	2 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Usually	4 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Sometimes	4 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Usually	2 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Always	15 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Never	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	4 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Always	13 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Rarely	2 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	4 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Usually	4 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Always	13 Participants	11 Participants

SECONDARY outcome

Timeframe: Visit 6 (Day 83-97)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Never	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 7 (Day 173-187)

Population: The All Randomized Per-Protocol (PP) population includes randomized participants who were compliant with the intervention administration regardless of cocci-status and have coccidioidal serology data available at the Day 1 and 22 visits.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing family activities I want to do · Usually	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized Per Protocol Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Never	1 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Rarely	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Sometimes	7 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Rarely	3 Participants	2 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Sometimes	5 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Always	14 Participants	12 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Sometimes	7 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Usually	3 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Always	15 Participants	13 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Never	0 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Rarely	3 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Sometimes	4 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Usually	5 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Always	15 Participants	15 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Rarely	5 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Usually	4 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Always	11 Participants	13 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Never	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Usually	4 Participants	7 Participants

SECONDARY outcome

Timeframe: Visit 3 (Day 27-30)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Rarely	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Sometimes	6 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Always	13 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Sometimes	6 Participants	7 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Usually	5 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Always	13 Participants	11 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Usually	4 Participants	13 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Rarely	2 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Sometimes	6 Participants	11 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Usually	4 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Always	14 Participants	9 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Rarely	4 Participants	3 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Sometimes	5 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Usually	4 Participants	10 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Always	13 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Rarely	2 Participants	3 Participants

SECONDARY outcome

Timeframe: Visit 4 (Day 42-46)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Usually	4 Participants	8 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Usually	2 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Usually	4 Participants	11 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Rarely	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Sometimes	6 Participants	6 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Always	14 Participants	12 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Rarely	2 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Sometimes	5 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Always	16 Participants	15 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Never	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Rarely	1 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Sometimes	5 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Always	14 Participants	11 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Rarely	2 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Sometimes	5 Participants	5 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Usually	4 Participants	4 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Always	14 Participants	16 Participants

SECONDARY outcome

Timeframe: Visit 6 (Day 83-97)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Never	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Visit 7 (Day 173-187)

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The PROMIS Ability to Participate in Social Roles and Activities - Short Form 4a uses 4 questions to measure the participant's ability to participate in social roles and activities in the context of family, friends, leisure, and work. Four individual items are answered as "Never", "Rarely", "Sometimes", "Usually", or "Always" with an "Always" response indicating the most trouble participating in social roles and activities.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing regular leisure activities w others · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Usually	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing family activities I want to do · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Rarely	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Sometimes	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing usual work (incl work at home) · Always	3 Participants	1 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Never	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Rarely	1 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Sometimes	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Usually	0 Participants	0 Participants
Number of Participants Responding to the Individual Items of the PROMIS Item Bank v2.0 - Ability to Participate in Social Roles and Activities - Short Form 4a in the All Randomized mITT Population Trouble doing activities with friends I want to do · Always	3 Participants	1 Participants

SECONDARY outcome

Timeframe: Day 1 through Day 43

Population: The population includes all participants who took at least one dose of study medication.

Mortality information was obtained through medical records or next of kin.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
Incidence Rate of All-cause Mortality	0 participants	0 participants

SECONDARY outcome

Timeframe: Visit 2 (Day 20-23)

Population: Intent-to-Treat (ITT) population - This efficacy analysis population includes all randomized participants.

The Modified Scoring System for Evaluating Treatment Response in Early Coccidioidal Pneumonia (FLEET CAP) score is a clinical scoring system that allows a constellation of clinical symptoms to be quantified and scored over time: cough, fatigue, chest pain, dyspnea, sputum production, night sweats, fever and hypoxia. The recall period for symptom assessments was during the past week, with the exception of fever and hypoxia, which was measured on the day the FLEET CAP was administered. All symptoms are graded on a 0-3 severity scale, except for night sweats and hypoxia which are graded on a 0-2 severity scale, where 0 indicates the symptom is absent or normal. The range of total scores is from 0-22, where higher scores correspond to a worse outcome.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Proportion of Participants Who Achieve a Clinical Response, Defined as at Least a 50% Reduction in Composite FLEET CAP Score From Baseline, in All Randomized Participants, Regardless of Coccidioidomycosis Status or Adherence to Study Drug	20 Participants	22 Participants

SECONDARY outcome

Timeframe: Day 1

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=32 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=39 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	48.2 score on a scale Standard Deviation 10.1	49.0 score on a scale Standard Deviation 10.2
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	38.6 score on a scale Standard Deviation 11.1	39.7 score on a scale Standard Deviation 9.8

SECONDARY outcome

Timeframe: Day 22

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	51.4 score on a scale Standard Deviation 10.0	49.4 score on a scale Standard Deviation 10.7
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	45.4 score on a scale Standard Deviation 11.2	44.2 score on a scale Standard Deviation 12.0

SECONDARY outcome

Timeframe: Day 29

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	49.5 score on a scale Standard Deviation 10.6	50.6 score on a scale Standard Deviation 9.9
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	47.9 score on a scale Standard Deviation 10.5	46.2 score on a scale Standard Deviation 11.5

SECONDARY outcome

Timeframe: Day 43

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	52.4 score on a scale Standard Deviation 10.0	51.3 score on a scale Standard Deviation 8.7
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	50.1 score on a scale Standard Deviation 8.9	46.2 score on a scale Standard Deviation 11.2

SECONDARY outcome

Timeframe: Day 90

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	51.5 score on a scale Standard Deviation 13.1	49.5 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	52.9 score on a scale Standard Deviation 9.0	55.5 score on a scale

SECONDARY outcome

Timeframe: Day 180

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	55.3 score on a scale Standard Deviation 9.8	61.1 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	46.9 score on a scale Standard Deviation 9.1	57.7 score on a scale

SECONDARY outcome

Timeframe: Day 1

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the subject needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population MCS	52.0 score on a scale Standard Deviation 6.3	37.1 score on a scale Standard Deviation 8.3
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population PCS	46.2 score on a scale Standard Deviation 15.4	45.3 score on a scale Standard Deviation 1.9

SECONDARY outcome

Timeframe: Day 22

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the subject needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population MCS	51.6 score on a scale Standard Deviation 8.3	43.7 score on a scale Standard Deviation 9.6
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population PCS	49.6 score on a scale Standard Deviation 12.3	60.1 score on a scale Standard Deviation 1.5

SECONDARY outcome

Timeframe: Day 29

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the subject needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population MCS	54.0 score on a scale Standard Deviation 11.3	43.9 score on a scale Standard Deviation 24.3
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population PCS	51.6 score on a scale Standard Deviation 11.0	60.1 score on a scale Standard Deviation 3.4

SECONDARY outcome

Timeframe: Day 43

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the subject needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population MCS	53.6 score on a scale Standard Deviation 12.2	50.2 score on a scale Standard Deviation 15.5
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population PCS	53.6 score on a scale Standard Deviation 7.0	58.9 score on a scale Standard Deviation 1.7

SECONDARY outcome

Timeframe: Day 90

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the subject needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population MCS	51.5 score on a scale Standard Deviation 13.1	49.5 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population PCS	52.9 score on a scale Standard Deviation 9.0	55.5 score on a scale

SECONDARY outcome

Timeframe: Day 180

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the subject needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population MCS	55.3 score on a scale Standard Deviation 9.8	61.1 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive PP Population PCS	46.9 score on a scale Standard Deviation 9.1	57.7 score on a scale

SECONDARY outcome

Timeframe: Day 1

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=4 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population MCS	52.0 score on a scale Standard Deviation 6.3	39.0 score on a scale Standard Deviation 12.3
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population PCS	46.2 score on a scale Standard Deviation 15.4	42.2 score on a scale Standard Deviation 10.5

SECONDARY outcome

Timeframe: Day 22

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=3 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population MCS	51.6 score on a scale Standard Deviation 8.3	40.6 score on a scale Standard Deviation 8.7
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population PCS	49.6 score on a scale Standard Deviation 12.3	47.4 score on a scale Standard Deviation 22.1

SECONDARY outcome

Timeframe: Day 29

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population MCS	54.0 score on a scale Standard Deviation 11.3	43.9 score on a scale Standard Deviation 24.3
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population PCS	51.6 score on a scale Standard Deviation 11.0	60.1 score on a scale Standard Deviation 3.4

SECONDARY outcome

Timeframe: Day 43

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population MCS	53.6 score on a scale Standard Deviation 12.2	50.2 score on a scale Standard Deviation 15.5
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population PCS	53.6 score on a scale Standard Deviation 7.0	58.9 score on a scale Standard Deviation 1.7

SECONDARY outcome

Timeframe: Day 90

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population PCS	52.9 score on a scale Standard Deviation 9.0	55.5 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population MCS	51.5 score on a scale Standard Deviation 13.1	49.5 score on a scale

SECONDARY outcome

Timeframe: Day 180

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population MCS	55.3 score on a scale Standard Deviation 9.8	61.1 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive mITT Population PCS	46.9 score on a scale Standard Deviation 9.1	57.7 score on a scale

SECONDARY outcome

Timeframe: Day 1

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=29 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	49.1 score on a scale Standard Deviation 10.2	47.9 score on a scale Standard Deviation 9.5
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	39.4 score on a scale Standard Deviation 11.6	39.6 score on a scale Standard Deviation 10.0

SECONDARY outcome

Timeframe: Day 22

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=29 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	51.7 score on a scale Standard Deviation 9.3	49.6 score on a scale Standard Deviation 10.8
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	45.9 score on a scale Standard Deviation 11.3	43.2 score on a scale Standard Deviation 11.4

SECONDARY outcome

Timeframe: Day 29

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=25 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	50.5 score on a scale Standard Deviation 10.2	50.8 score on a scale Standard Deviation 10.3
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	48.3 score on a scale Standard Deviation 10.7	45.3 score on a scale Standard Deviation 11.9

SECONDARY outcome

Timeframe: Day 43

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=22 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=24 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	53.3 score on a scale Standard Deviation 10.0	49.8 score on a scale Standard Deviation 9.0
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	50.5 score on a scale Standard Deviation 9.1	46.0 score on a scale Standard Deviation 11.0

SECONDARY outcome

Timeframe: Day 90

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	51.5 score on a scale Standard Deviation 13.1	49.5 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	52.9 score on a scale Standard Deviation 9.0	55.5 score on a scale

SECONDARY outcome

Timeframe: Day 180

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	55.3 score on a scale Standard Deviation 9.8	61.1 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	46.9 score on a scale Standard Deviation 9.1	57.7 score on a scale

SECONDARY outcome

Timeframe: Day 1

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=32 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=39 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	48.2 score on a scale Standard Deviation 10.1	49.0 score on a scale Standard Deviation 10.2
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	38.6 score on a scale Standard Deviation 11.1	39.7 score on a scale Standard Deviation 9.8

SECONDARY outcome

Timeframe: Day 22

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	51.4 score on a scale Standard Deviation 10.0	49.4 score on a scale Standard Deviation 10.7
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	45.4 score on a scale Standard Deviation 11.2	44.2 score on a scale Standard Deviation 12.0

SECONDARY outcome

Timeframe: Day 29

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	49.5 score on a scale Standard Deviation 10.6	50.6 score on a scale Standard Deviation 9.9
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	47.9 score on a scale Standard Deviation 10.5	46.2 score on a scale Standard Deviation 11.5

SECONDARY outcome

Timeframe: Day 43

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	52.4 score on a scale Standard Deviation 10.0	51.3 score on a scale Standard Deviation 8.7
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	50.1 score on a scale Standard Deviation 8.9	46.2 score on a scale Standard Deviation 11.2

SECONDARY outcome

Timeframe: Day 90

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	51.5 score on a scale Standard Deviation 13.1	49.5 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	52.9 score on a scale Standard Deviation 9.0	55.5 score on a scale

SECONDARY outcome

Timeframe: Day 180

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	55.3 score on a scale Standard Deviation 9.8	61.1 score on a scale
The Mean for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	46.9 score on a scale Standard Deviation 9.1	57.7 score on a scale

SECONDARY outcome

Timeframe: Day 1

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=32 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=39 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	50.0 score on a scale Interval 41.1 to 56.4	49.6 score on a scale Interval 42.0 to 56.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	39.1 score on a scale Interval 30.1 to 45.2	39.1 score on a scale Interval 31.9 to 46.7

SECONDARY outcome

Timeframe: Day 22

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	54.9 score on a scale Interval 44.5 to 59.1	50.5 score on a scale Interval 43.1 to 59.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	46.5 score on a scale Interval 35.5 to 55.7	46.0 score on a scale Interval 33.4 to 56.0

SECONDARY outcome

Timeframe: Day 29

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	54.5 score on a scale Interval 40.2 to 57.8	52.9 score on a scale Interval 43.1 to 58.2
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	52.5 score on a scale Interval 39.3 to 57.2	47.5 score on a scale Interval 36.8 to 57.2

SECONDARY outcome

Timeframe: Day 43

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	56.4 score on a scale Interval 43.1 to 60.2	54.1 score on a scale Interval 46.6 to 59.0
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	53.5 score on a scale Interval 44.8 to 56.7	48.6 score on a scale Interval 41.2 to 53.8

SECONDARY outcome

Timeframe: Day 90

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	56.4 score on a scale Interval 44.3 to 58.8	49.5 score on a scale Interval 49.5 to 49.5
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	57.2 score on a scale Interval 48.3 to 57.5	55.5 score on a scale Interval 55.5 to 55.5

SECONDARY outcome

Timeframe: Day 180

Population: The Intent-to-Treat (ITT) population includes all randomized participants with data at the time point.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population MCS	59.2 score on a scale Interval 49.2 to 61.5	61.1 score on a scale Interval 61.1 to 61.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, ITT Population PCS	50.9 score on a scale Interval 41.7 to 52.1	57.7 score on a scale Interval 57.7 to 57.7

SECONDARY outcome

Timeframe: Day 1

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population MCS	52.7 score on a scale Interval 46.8 to 57.2	37.1 score on a scale Interval 31.3 to 43.0
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population PCS	51.2 score on a scale Interval 35.0 to 57.4	45.3 score on a scale Interval 43.9 to 46.7

SECONDARY outcome

Timeframe: Day 22

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population MCS	54.5 score on a scale Interval 46.7 to 56.5	43.7 score on a scale Interval 36.9 to 50.5
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population PCS	53.5 score on a scale Interval 42.2 to 57.0	60.1 score on a scale Interval 59.0 to 61.1

SECONDARY outcome

Timeframe: Day 29

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population MCS	58.8 score on a scale Interval 46.9 to 61.2	43.9 score on a scale Interval 26.8 to 61.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population PCS	56.7 score on a scale Interval 45.6 to 57.5	60.1 score on a scale Interval 57.7 to 62.5

SECONDARY outcome

Timeframe: Day 43

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population MCS	58.8 score on a scale Interval 46.0 to 61.2	50.2 score on a scale Interval 39.2 to 61.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population PCS	56.7 score on a scale Interval 49.7 to 57.5	58.9 score on a scale Interval 57.7 to 60.1

SECONDARY outcome

Timeframe: Day 90

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population MCS	56.4 score on a scale Interval 44.3 to 58.8	49.5 score on a scale Interval 49.5 to 49.5
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population PCS	57.2 score on a scale Interval 48.3 to 57.5	55.5 score on a scale Interval 55.5 to 55.5

SECONDARY outcome

Timeframe: Day 180

Population: The cocci-positive per-protocol population includes randomized participants who met the case definition of cocci pneumonia, were adherent with the intervention and had coccidioidal serology data available at the Day 1 and 22 visits. To be considered adherent at the Day 22 visit, the participant needed to take \>=80% of their expected pills.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population MCS	59.2 score on a scale Interval 49.2 to 61.5	61.1 score on a scale Interval 61.1 to 61.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci-positive Per-protocol Population PCS	50.9 score on a scale Interval 41.7 to 52.1	57.7 score on a scale Interval 57.7 to 57.7

SECONDARY outcome

Timeframe: Day 1

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=4 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population MCS	52.7 score on a scale Interval 46.8 to 57.2	37.1 score on a scale Interval 29.3 to 48.8
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population PCS	51.2 score on a scale Interval 35.0 to 57.4	45.3 score on a scale Interval 35.6 to 48.9

SECONDARY outcome

Timeframe: Day 22

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=3 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population MCS	54.5 score on a scale Interval 46.7 to 56.5	36.9 score on a scale Interval 34.4 to 50.5
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population PCS	53.5 score on a scale Interval 42.2 to 57.0	59.0 score on a scale Interval 21.9 to 61.1

SECONDARY outcome

Timeframe: Day 29

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population MCS	58.8 score on a scale Interval 46.9 to 61.2	43.9 score on a scale Interval 26.8 to 61.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population PCS	56.7 score on a scale Interval 45.6 to 57.5	60.1 score on a scale Interval 57.7 to 62.5

SECONDARY outcome

Timeframe: Day 43

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=2 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population MCS	58.8 score on a scale Interval 46.0 to 61.2	50.2 score on a scale Interval 39.2 to 61.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population PCS	56.7 score on a scale Interval 49.7 to 57.5	58.9 score on a scale Interval 57.7 to 60.1

SECONDARY outcome

Timeframe: Day 90

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population MCS	56.4 score on a scale Interval 44.3 to 58.8	49.5 score on a scale Interval 49.5 to 49.5
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population PCS	57.2 score on a scale Interval 48.3 to 57.5	55.5 score on a scale Interval 55.5 to 55.5

SECONDARY outcome

Timeframe: Day 180

Population: Cocci Positive Modified Intent-to-Treat (mITT) population includes all randomized participants who meet the case definition of coccidioidomycosis pneumonia and took at least one dose of study medication. Note that it was not necessary for a participant to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population MCS	59.2 score on a scale Interval 49.2 to 61.5	61.1 score on a scale Interval 61.1 to 61.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, Cocci Positive Modified Intent-to-Treat Population PCS	50.9 score on a scale Interval 41.7 to 52.1	57.7 score on a scale Interval 57.7 to 57.7

SECONDARY outcome

Timeframe: Day 1

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=29 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	51.1 score on a scale Interval 44.4 to 56.4	47.9 score on a scale Interval 40.7 to 54.9
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	39.7 score on a scale Interval 31.1 to 46.5	39.2 score on a scale Interval 31.9 to 46.1

SECONDARY outcome

Timeframe: Day 22

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=25 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=29 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	54.9 score on a scale Interval 44.7 to 58.5	50.5 score on a scale Interval 43.1 to 59.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	48.3 score on a scale Interval 36.3 to 55.7	45.3 score on a scale Interval 33.4 to 53.2

SECONDARY outcome

Timeframe: Day 29

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=25 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	55.6 score on a scale Interval 42.9 to 58.3	53.3 score on a scale Interval 44.2 to 58.2
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	52.9 score on a scale Interval 40.0 to 57.2	46.9 score on a scale Interval 36.8 to 54.8

SECONDARY outcome

Timeframe: Day 43

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=22 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=24 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	57.2 score on a scale Interval 51.7 to 61.1	49.6 score on a scale Interval 43.3 to 58.4
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	54.0 score on a scale Interval 46.3 to 57.2	48.2 score on a scale Interval 38.5 to 53.6

SECONDARY outcome

Timeframe: Day 90

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	56.4 score on a scale Interval 44.3 to 58.8	49.5 score on a scale Interval 49.5 to 49.5
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	57.2 score on a scale Interval 48.3 to 57.5	55.5 score on a scale Interval 55.5 to 55.5

SECONDARY outcome

Timeframe: Day 180

Population: The All-Randomized PP population includes all participants who took at least one dose of study medication.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population MCS	59.2 score on a scale Interval 49.2 to 61.5	61.1 score on a scale Interval 61.1 to 61.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized PP Population PCS	50.9 score on a scale Interval 41.7 to 52.1	57.7 score on a scale Interval 57.7 to 57.7

SECONDARY outcome

Timeframe: Day 1

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=32 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=39 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	50.0 score on a scale Interval 41.1 to 56.4	49.6 score on a scale Interval 42.0 to 56.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	39.1 score on a scale Interval 30.1 to 45.2	39.1 score on a scale Interval 31.9 to 46.7

SECONDARY outcome

Timeframe: Day 22

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=27 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=35 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	54.9 score on a scale Interval 44.5 to 59.1	50.5 score on a scale Interval 43.1 to 59.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	46.5 score on a scale Interval 35.5 to 55.7	46.0 score on a scale Interval 33.4 to 56.0

SECONDARY outcome

Timeframe: Day 29

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=26 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=31 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	54.5 score on a scale Interval 40.2 to 57.8	52.9 score on a scale Interval 43.1 to 58.2
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	52.5 score on a scale Interval 39.3 to 57.2	47.5 score on a scale Interval 36.8 to 57.2

SECONDARY outcome

Timeframe: Day 43

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=24 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=30 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	56.4 score on a scale Interval 43.1 to 60.2	54.1 score on a scale Interval 46.6 to 59.0
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	53.5 score on a scale Interval 44.8 to 56.7	48.6 score on a scale Interval 41.2 to 53.8

SECONDARY outcome

Timeframe: Day 90

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	56.4 score on a scale Interval 44.3 to 58.8	49.5 score on a scale Interval 49.5 to 49.5
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	57.2 score on a scale Interval 48.3 to 57.5	55.5 score on a scale Interval 55.5 to 55.5

SECONDARY outcome

Timeframe: Day 180

Population: All Randomized Modified Intent-to-Treat (mITT) population - This efficacy analysis population includes all randomized participants who took at least one dose of study medication regardless of cocci-status. Note that it is not necessary for a participants to be adherent to study drug to be eligible for inclusion in the mITT population.

The SF-12v2 uses 12 questions to measure functional health and well-being from the study participant's perspective across eight domains: physical functioning, role, bodily pain, general health perceptions, vitality, social functioning, emotional role, and mental health. Mental and physical composite scores (MCS \& PCS) are computed using the scores of twelve questions and range from 0 to 100, where a higher score indicates better health.

Outcome measures

Outcome measures
Measure	Fluconazole n=4 Participants Fluconazole was supplied as 200mg over encapsulated tablets. Each gelatin capsule contained two-100mg fluconazole tablets and microcrystalline cellulose for overfill. Fluconazole 400 mg (administered orally as two 200mg capsules) was to be taken once daily for a minimum of 42 days.	Placebo n=1 Participants Placebo was supplied as matching gelatin capsules containing microcrystalline cellulose only. In order to maintain the blind, the gelatin capsules were the same size, weight, and color as the capsules containing fluconazole tablets. Placebo (administered orally as two matching placebo capsules) was to be taken once daily for a minimum of 42 days.
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population MCS	59.2 score on a scale Interval 49.2 to 61.5	61.1 score on a scale Interval 61.1 to 61.1
The Median for the Mental Component Summary (MCS) and the Physical Component Summary (PCS) Scores of the SF-12v2 Instrument, All Randomized mITT Population PCS	50.9 score on a scale Interval 41.7 to 52.1	57.7 score on a scale Interval 57.7 to 57.7

Adverse Events

Fluconazole

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Placebo

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Emmanuel Walter, M.D., M.P.H.

Duke Clinical Vaccine Unit

Phone: 919-620-5346

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: LTE60